The Influence of Polymorphism of the Μ-opioid Receptor OPRM1 A118G on the Doses of Narcotic Analgesics in the Early Postoperative Period (Meta-Analysis)

Abstract

Objectives of the study was the compilation and analysis of available data on the influence of polymorphism of the μ-opioid receptor OPRM1 A118G on the doses of narcotic analgesics in the early postoperative period. Material and methods. The information was taken from SCOPUS, MedLine, EMBASE. We analyzed 34 studies. The inclusion criteria in meta-analysis: the original study on this issue. Exclusion criteria: reviews, articles concerning the influence of polymorphism on pain not related to surgical treatment (childbirth, cancer pain, chronic pain), as well as papers in which the authors studied the influence of polymorphism of the μ-opioid receptor OPRM1 A118G on the doses of narcotic analgesics infused in the epidural or intrathecal space. 6 works (1691 patients) were included in the meta-analysis. We analyzed the difference in the need for narcotic analgesics in the first 24 hour. Results. We found that homozygous carriers of A-allele of the μ-opioid receptor OPRM1 needed lower doses of narcotic analgesics compared with heterozygous (fixed effects model; Z = −10,172; p = 0.0001; I2 = 54.1 per cent), and homozygous carriers of G-allele(fixed effects model; Z = −6,543; p = 0.0001; I2= 81,7 %). Conclusion. Polymorphism of the μ-opioid receptor OPRM1 A118G affects the individual need for narcotic analgesics in the early postoperative period.